An injection for lose weight? It is a reality, thanks to the Danish pharmaceutical company Novo Nordisk and something dreamed of by many, which may seem typical of futurism. But it is here, and the expectation and faith in the product is such that the company has become the most valuable in Europe thanks to this product.
Times change, and the previous most valued company was the French luxury conglomerate, LVMH, which has brands such as Louis Vuitton. And luxury is still sought, but above all health and a body of ten. If it can also be achieved with an injection, the ascension of Novo Nordisk in the markets.
A revolutionary new medicine
The huge rise in the shares of the Danish company, with a stock market valuation of $428 billion, is due to the launch, after its development, of Wegovy. For now It is only available in the United Kingdom, but there is already high demand in several countries.
The medicine is aimed at people suffering from obesity. It is injected once a week and the key is that it gives the recipient a clear feeling of satiety, so they eat less and consequently lose weight. Wegovy works by mimicking a hormone called glucagon-like peptide 1 (GLP-1) that targets areas of the brain that regulate appetite.
The celebrities couldn’t be missing
Faced with these medical and scientific developments, celebrities and celebrities are always very attentive, willing to try it to have better health and longevity, something that many of them are obsessed with.
It is the case of Elon Musk, who uses Wegoby, despite not being obese, but being overweight. Other Hollywood personalities, but also the American population in general, are using the drug. In this country, the drug was approved and regulated in 2021. They always tend to stay ahead of the slower and tougher European regulations.
A country in love with diets and miraculous treatments
The United States is where these types of medications and treatments are most consumed, whether they have been legalized or not. In addition to Wegoby, Ozempic also triumphs, in this case against diabetes.
These types of medications are always under scrutiny and are a source of scientific controversy, despite all the tests that are carried out before their sale and consumption. Even so, Experts always warn and recommend that there is nothing like a healthy diet and exercise.that is, doing it naturally and through perseverance.
Bread for today and hunger for tomorrow?
In light of what happens with Many of the consumers who stopped taking Wegoby, that’s right, since they regain the lost weight. The reason is obvious: by not basing this decrease on sacrifice, diet and exercise, when you stop injecting you return to being as hungry as before and eating as before.
Even so, the fever from this medicine is obvious: Novo Nordisk It continues to receive orders from Wegoby, but since it does not have enough units, it has to limit shipments and make plans to increase its manufacturing.
The curious thing about a surprised company
The most surprising thing is that the Danish company did not expect such success and that they are even concerned about the danger of users using the treatment inappropriatelywith the consequences that it may have and the bad image on the company that it would result in, which in turn would make its value plummet, with the same intensity or greater than what it has risen.
All this despite the fact that the guidelines of the United Kingdom National Health Service are clear: only use the medication and treatment in cases of significant overweight or obesity. In any case, the success in this country is logical, since it is where there are the most obese people in Europe, one in three adults, according to the Organization for Economic Cooperation and Development (OECD).
The American epidemic
But next to the US data, the United Kingdom does not seem so serious. In United States 70% of the adult population is obese or overweight, according to data from the Food and Drug Administration. Perhaps that is why they are more lax when it comes to approving treatments like these.
Additionally, a new trial has shown that Wegovy reduces the risk of suffering a stroke or heart attack, although this remains to be confirmed. New premises so that demand in this country or others continues to grow.
2023-09-08 09:15:08
#Danish #pharmaceutical #company #succeeds #weight #loss #vaccine
